Received May 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
Weakness/Loss of strength; Headache; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of weakness in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced weakness (Verbatim: Weakness/Loss of strength) and headache (Verbatim: Headache). The outcome of the weakness and headache were not reported. It was unknown if the reporter considered the weakness and headache to be related to Shingrix. It was unknown if the company considered the weakness and headache to be related to Shingrix. Additional Information: GSK Receipt Date: 07-MAY-2025 This case was reported by a patient via (Shingrix GSK Chatbot) interactive digital media. The patient received Shingrix vaccine had weakness, headache, loss of strength. The reporter was ask could he/she took aspirin or Tylenol, was there anything to use to get rid of the scars and what to did if the second Shingrix dose was missed.